Alpha Cognition (NASDAQ:ACOG) Announces Earnings Results

Alpha Cognition (NASDAQ:ACOG) released its earnings results on Thursday. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.04, Zacks reports. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 62.07%. The business had revenue of $3.53 million during the quarter, compared to analysts’ expectations of $3.42 million.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL commercialization accelerated in Q1 2026, with net product revenue rising 40% sequentially to $3.5 million and March delivering the strongest demand month since launch, with April said to be even stronger.
• Commercial adoption metrics improved across the board: bottles dispensed rose 23%, active HCP writers increased to 1,060, and nursing homes with prescriptions grew 25%, while repeat prescribing and repeat facility orders remained strong.
• The company reiterated its 2026 operating expense guidance of $54 million to $58 million and said it remains on track to reach operating profitability in 2027, supported by a $54.2 million cash balance and no debt.
• Alpha Cognition said its real-world evidence studies are advancing faster than expected, with BEACON enrollment expected to finish this quarter and top-line data due by early Q3, while CONVERGE and RESOLVE are also set to progress in 2026.
• The company strengthened its intellectual property around ZUNVEYL with two new U.S. patents extending protection through 2045, and it highlighted a large addressable opportunity for its traumatic brain injury program.

Alpha Cognition Stock Up 6.0%

ACOG traded up $0.34 during trading on Friday, hitting $6.02. The company had a trading volume of 96,130 shares, compared to its average volume of 36,966. The company has a market capitalization of $131.08 million, a PE ratio of -4.46 and a beta of 2.38. Alpha Cognition has a one year low of $4.50 and a one year high of $11.54. The firm’s 50-day moving average price is $6.07 and its 200 day moving average price is $5.92.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ACOG shares. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Alpha Cognition in a research note on Monday, April 27th. Wall Street Zen cut shares of Alpha Cognition from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Finally, Craig Hallum initiated coverage on shares of Alpha Cognition in a report on Friday, April 17th. They set a “buy” rating and a $14.00 price objective for the company. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $16.00.

Institutional Investors Weigh In On Alpha Cognition

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC acquired a new position in shares of Alpha Cognition during the 2nd quarter worth about $112,000. Massar Capital Management LP acquired a new position in shares of Alpha Cognition during the 2nd quarter worth about $116,000. Two Sigma Investments LP acquired a new position in shares of Alpha Cognition during the 3rd quarter worth about $148,000. Boothbay Fund Management LLC increased its stake in shares of Alpha Cognition by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 291,868 shares of the company’s stock worth $1,900,000 after purchasing an additional 28,392 shares during the last quarter. Finally, Connective Capital Management LLC acquired a new position in shares of Alpha Cognition during the 3rd quarter worth about $312,000.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.